Single-agent docetaxel (TXT) as first-line treatment in metastatic breast cancer (MBC)

11515 Background: Historically anthracyclines have been considered the most active agents in metastatic breast cancer (MBC). Docetaxel (TXT) has challenged this belief. Aims: Evaluate response rates, toxicity and time to progression in patients with MBC receiving single agent TXT as first line treatment. Methods: MBC patients received first line single agent treatment according to one of the following schedules: TXT 35 mg/m2 iv weekly for 6 wks q 8 wks (Group 1) or TXT 100 mg/m2 iv day 1 q 3 weeks (Group 2). Adjuvant chemotherapy was FAC (600,50,600) day 1 q 21 days for 6 courses in all cases so treated. Results: Conclusions: It appears that results with single agent TXT obtained in clinical practice are comparable to those reported in Phase II-III trials (Group 1 and Group 2, respectively ) using the same regimens. Group 1 (Weekly) Group 2 (q 21 days) Number of patients 36 28 Median age (yr) 56 59 Range (yr) 32–81 27–70 Prior adjuvant chemotherapy 26 12 Objective Response (CR + PR) 22% 45% Median time to...